Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：232

作者：

Verheijen, Remy B. ^{[1
]}

Yu, Huixin ^{[1
]}

Schellens, Jan H. M. ^{[2
,3
]}

Beijnen, Jos H. ^{[1
,3
]}

Steeghs, Neeltje ^{[2
]}

Huitema, Alwin D. R. ^{[1
,4
]}

机构：

[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands

[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands

[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期

关键词：

CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;

D O I：

10.1002/cpt.787

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

引用

页码：765 / 776

页数：12

共 50 条

[21] Tyrosin kinase inhibitors in oncology
Zander, T.
Hallek, M.
INTERNIST, 2011, 52 (05): : 595 - 600
[22] A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)
Domingos, Vera
Nezvalova-Henriksen, Katerina
Dadkhah, Adrin
Moreno-Martinez, Maria-Estela
Ben Hassine, Khalil
Pires, Vera
Kroeger, Nicolaus
Bauters, Tiene
Hassan, Moustapha
Duncan, Nick
Kalwak, Krzysztof
Ansari, Marc
Langebrake, Claudia
Admiraal, Rick
BONE MARROW TRANSPLANTATION, 2024, 59 (12) : 1641 - 1653
[23] Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia
Widmer, N.
Gotta, V.
Haouala, A.
Decosterd, L. A.
LEUKEMIA RESEARCH, 2010, 34 (06) : 698 - 699
[24] Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report
Strobbe, Geoffrey
Pannier, Diane
Sakji, Ilyes
Villain, Alexandre
Feutry, Frederic
Marliot, Guillaume
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1743 - 1749
[25] Therapeutic drug monitoring in cancer chemotherapy
Bach, Dylan M.
Straseski, Joely A.
Clarke, William
BIOANALYSIS, 2010, 2 (05) : 863 - 879
[26] A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
Vaughn, Byron P.
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
[27] Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
Liu, Dongxue
Hu, Linlin
Shao, Hua
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (03) : 165 - 179
[28] Level of Evidence for Therapeutic Drug Monitoring of Cisplatin
Hulin, Anne
Royer, Bernard
Chatelut, Etienne
Le Guellec, Chantal
THERAPIE, 2010, 65 (03): : 151 - 155
[29] Level of Evidence for Therapeutic Drug Monitoring for Docetaxel
Gerritsen-van Schieveen, Pauline
Royer, Bernard
THERAPIE, 2010, 65 (03): : 201 - 206
[30] Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies
Li, Ninghong
Liu, Lu
Liu, Dong
Yu, Hengyi
Yang, Guangjie
Qiu, Lihui
Chen, Yufei
Xiang, Dong
Gong, Xuepeng
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2024, 1246

← 1 2 3 4 5 →